Industry Projects
| Anti-Infective | Cardiovascular |
| CNS and GI | Metabolic Disorders |
| Musculoskeletal and Skin Disorders | Oncology |
| Respiratory |
Top- Ceftobiprole Medocaril - Injectable Anti-MRSA Cephalosporin Antibiotic
- Dalvabancin - Second-Generation Glycopeptide for Serious Gram-Positive Infections
- Doripenem - A New Broad-Spectrum Carabapenem Antibiotic
- Fludase - Experimental Antiviral Drug for Influenza
- INCB9471 – CCR5 Antagonist for Treatment of HIV Infection
- Maraviroc - Therapy for Treatment of HIV Infection
- Merck Isentress - Emerging Therapy for Treatment of HIV Infection, USA
- Motavizumab - New Biological Therapy for RSV Prevention, USA
- Oritavancin - Glycopeptide Antibiotic for Multidrug-Resistant Gram-Positive Pathogens
- Rupintrivir - Experimental Treatment for the Common Cold
- T-705 - Antiviral Drug for Influenza
- Telbivudine - Investigational Drug for Chronic Hepatitis B Infection
- Tygacil - Broad-Spectrum Antibiotic for Empiric Treatment of Serious Infections
- Valtorcitabine - Combination Drug Therapy for Chronic Hepatitis B
- ETC-216 - Phospholipid Therapy for Coronary Heart Disease (CHD) Patients
- Exanta - Oral Direct Thrombin Inhibitor for the Prevention and Treatment of Venous Thromboembolism
- Idraparinux - Investigational Agent for the Treatment and Prevention of Thromboembolic Events
- Istaroxime - Agent for Congestive Heart Failure, Switzerland
- Multaq - Investigational Agent for the Treatment of Cardiac Arrhythmia
- Pradaxa – Oral Direct Thrombin Inhibitor
- Prasugrel - Investigational Antiplatelet Agent
- TRA-SCH-530348 -Oral Antiplatelet Agent
- Xarelto - Investigational Agent for Treatment and Prevention of Thromboembolic Events
- APD125 - Therapy for Insomnia, USA
- Bifeprunox - Atypical Antipsychotic Drug
- Caprospinol, Therapy for Alzheimer's Disease (AD)
- Cerovive - Neuroprotectant for the Treatment of Acute Ischaemic Stroke
- Cilansetron - New Treatment for IBS
- Fampridine-SR – Treatment for Multiple Sclerosis
- Flurizan – Anti-Amyloid Drug for Treatment of Alzheimer’s Disease
- Gaboxadol - Investigational Agent for the Treatment of Sleep Disorders
- HCT 3012 - COX-Inhibiting Nitric Oxide-Donator (CINOD) for Relief of Pain and Inflammation
- Iloperidone - Atypical Antipsychotic for Schizophrenia
- Licofelone - Novel Analgesic and Anti-Inflammatory Agent for Osteoarthritis
- LY2140023 – Treatment of Schizophrenia
- Lyrica (Pregabalin) - New Gabapentinoid with Wide Clinical Application
- M6G, A New Morphine Derivative For Post-Operative Pain Relief
- Mylinax - Novel Therapy for the Treatment of Multiple Sclerosis
- NG2-73 - A Novel Agent For The Treatment of Insomnia
- Olcegepant - Novel Therapy for Acute Migraine
- Phenserine - Next Generation AChE Inhibitor for Alzheimer's Disease (AD)
- Prexige - COX-2 Inhibitor for the Relief of Pain and Inflammation
- Rasagiline - Second-Generation MAO-B Inhibitor for the Treatment of Parkinson's Disease
- Rezular – Oral Treatment for IBS
- Sativex - Investigational Cannabis-Based Treatment for Pain and Multiple Sclerosis
- Semagacestat – Gamma Secretase Inhibitor for Alzheimer's Disease (AD)
- Treximet - Next-Generation Treatment for Migraine
- Tysabri - Therapeutic Monoclonal Antibody (MAb) for the Treatment of Multiple Sclerosis
- V1512 - Treatment of Parkinson's Disease
- Vesicare - Oral Selective Muscarinic Receptor Antagonist for Overactive Bladder (OAB)
- Acomplia (Rimonabant) - Investigational Agent for the Management of Obesity
- Byetta - First-in-Class Incretin Mimetic for Type 2 Diabetes
- Cetilistat - Investigational Drug for Obesity
- Denosumab - Therapy for Prevention and Treatment of Osteoporosis
- Exubera - Inhaled Insulin for Type 1 and Type 2 Diabetes
- Galida - Dual PPAR Agonist for Type 2 Diabetes and Metabolic Syndrome
- Galvus (vildagliptin) - DPP-IV Inhibitor / Oral Antidiabetic Agent
- Liraglutide – Next-Generation Antidiabetic Medication
- Oporia (Lasofoxifene) - Investigational SERM for the Prevention and Treatment of Osteoporosis
- Oral-Lyn - Oral Insulin for Types 1 and 2 Diabetes
- Taranabant CB1 Receptor Inverse Agonist for Management of Obe
- Actemra - Biological Therapy for Rheumatoid Arthritis (RA), Switzerland
- Ustekinumab – Treatment for Plaque Psoriasis
- ASA404 Vascular Disrupting Agent for Solid Tumours, New Zealand
- Avastin (bevacizumab) - Angiogenesis Inhibitor and Cancer Therapy
- Cervarix – Cervical Cancer Vaccine
- Dasatinib - Tyrosine Kinase Inhibitor for Chronic Myeloid Leukaemia (CML)
- Erbitux (Cetuximab) - Investigational Biological Cancer Therapy
- Ixempra (Ixapebilone) – New Cancer Therapy
- Pertuzumab –Cancer Therapy
- RAD001 – Anti-Cancer Therapy
- Tarceva - Small Molecule EGFR-Tyrosine Kinase Inhibitor for Cancer
- Tesmilifene - Chemopotentiator for Cancer Therapies
- Tykerb - Dual Tyrosine Kinase Inhibitor for the Treatment of Solid Tumours
- Zactima - Tyrosine Kinase Inhibitor for Treatment of Lung Cancer
- Zybrestat - Vascular Disrupting Agent and Cancer Therapy
- Ariflo (Cilomilast) - Oral PDE-IV Inhibitor for Chronic Obstructive Pulmonary Disease (COPD)
- Xolair - Biological Therapy for the Treatment of Asthma
| INDUSTRY PROJECTS ARCHIVE |
Copyright 2008 SPG Media Limited a subsidiary of SPG Media Group PLC
